- 50% of patients with metastatic renal cell carcinoma (RCC) experience immune-related adverse events (irAEs) with immunotherapy rechallenge after discontinuation for toxicity.
- However, these irAEs are manageable, with no grade 4/5 toxicity or treatment-related deaths.
Why this matters
- These findings can guide clinicians on retreatment with immunotherapy.
- Further research is needed to identify patients likely to benefit from rechallenge.
- 80 patients with metastatic renal cell carcinoma treated who developed irAEs with immune-checkpoint inhibitors.
- 36 patients were rechallenged with immunotherapy, and 44 were permanently discontinued.
- Funding: None disclosed.
- Fewer retreatment patients required corticosteroids (55.6% vs 84.1%; P=.007) and hospitalizations (33.3% vs 65.9%; P=.007) for irAE management vs discontinued patients.
- 50% of retreated patients experienced subsequent irAEs (12 new and 6 recurrent; grade 3 events, 7; drug interruptions, 13).
- All irAEs with retreatment were grade ≤3 with no grade 4/5 events.
- Median time to irAE recurrence after retreatment was 2.8 months.
- In the discontinued vs retreatment groups:
- Overall response rate was 43% (95% CI, 28%-59%) vs 44% (28%-62%).
- 2-year OS was 66% (48%-79%) vs 76% (55%-88%).
- Retrospective design.